The role of CDK4/6 inhibitors in breast cancer

Simple item page
dc.check.date2020-05-18
dc.check.infoAccess to this article is restricted until 12 months after publication by request of the publisher.en
dc.contributor.authorMurphy, Conleth G.
dc.date.accessioned2019-07-16T09:53:09Z
dc.date.available2019-07-16T09:53:09Z
dc.date.issued2019-05-18
dc.description.abstractOral inhibitors of CDK4/6 have been shown to increase response rates and prolong disease control when combined with endocrine therapy in hormone-responsive (HR+) HER2-negative advanced breast cancer. Palbociclib, ribociclib and abemaciclib are all approved in combination with non-steroidal aromatase inhibitors in first-line therapy for post-menopausal women, with a 40–45% improvement in progression-free survival seen with the addition of any of these CDK4/6 inhibitors. Additional approved indications, including first- and second-line combination therapy for pre-menopausal women, combination with fulvestrant and use as monotherapy, vary with each agent and are reviewed fully in the subsequent texts. These agents also differ in their toxicity profiles and monitoring requirements, and prescribers should be aware of the individual requirements for each agent. Current clinical trials are investigating the expanded use of these agents in other breast cancer subtypes, such as HER2-positive and triple-negative breast cancer, as well as in the adjuvant and neoadjuvant treatments of early breast cancer. Resistance to CDK4/6 inhibition can occur through multiple mechanisms. Rational combinations with other therapies, such as PI3K inhibitors, HER2-directed therapies and immunotherapy, are being explored.en
dc.description.statusPeer revieweden
dc.description.versionAccepted Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.articleid52en
dc.identifier.citationMurphy, C. G. (2019) ‘The role of CDK4/6 inhibitors in breast cancer’, Current Treatment Options in Oncology, 20:52 (13pp). doi: 10.1007/s11864-019-0651-4en
dc.identifier.doi10.1007/s11864-019-0651-4en
dc.identifier.eissn1534-6277
dc.identifier.endpage13en
dc.identifier.issn1527-2729
dc.identifier.journaltitleCurrent Treatment Options in Oncologyen
dc.identifier.startpage1en
dc.identifier.urihttps://hdl.handle.net/10468/8167
dc.identifier.volume20en
dc.language.isoenen
dc.publisherSpringer Nature Switzerland AGen
dc.rights© 2019, Springer Science+Business Media, LLC, part of Springer Nature. This is a post-peer-review, pre-copyedit version of an article published in Current Treatment Options in Oncology. The final authenticated version is available online at: https://doi.org//10.1007/s11864-019-0651-4en
dc.subjectBreast canceren
dc.subjectClinical trialsen
dc.subjectCDK4/6 inhibitorsen
dc.subjectEndocrine therapyen
dc.subjectPalbocicliben
dc.subjectRibocicliben
dc.subjectAbemacicliben
dc.subjectEndocrine resistanceen
dc.subjectTriple-negative breast neoplasmsen
dc.subjectHER2-positive breast canceren
dc.titleThe role of CDK4/6 inhibitors in breast canceren
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
WITH FULL REF Role of CDK4_6 inhibitors in breast cancer chemotherapy.pdf
Size:
154.41 KB
Format:
Adobe Portable Document Format
Description:
Accepted Version
Download
Thumbnail Image
Name:
WITH FULL REF Role of CDK4_6 inhibitors in breast cancer chemotherapy.docx
Size:
48.79 KB
Format:
Microsoft Word XML
Description:
Author's Original Accepted Version
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medicine - Journal Articles